Steve Littlejohn

• 
  www.express-script.com/ourcompany/pressroom/mediareques - [Cached Version]
  Published on: 3/12/2007    Last Visited: 3/12/2007  

  Steve Littlejohn, vice president, public affairs314.702.7556slittlejohn@express-scripts.com

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/w - [Cached Version]
  Published on: 9/18/2008    Last Visited: 9/18/2008  

  Media Contact: Steve Littlejohn
  
  314.996-0981 slittlejohn@express-scripts.com

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 3/14/2007    Last Visited: 3/21/2007  

  Steve Littlejohn, VP, Public Affairs (314) 702-7556

• 
  phx.corporate-ir.net/phoenix.zhtml?c=69641&p=irol-newsA - [Cached Version]
  Last Visited: 3/2/2008  

  Steve Littlejohn, VP, Public Affairs(314) 702-7556
  ...
  CONTACT: Investor Contacts - Edward Stiften, Chief Financial Officer, or David Myers, Vice President, Investor Relations, +1-314-702-7173; Laurie Connell, MacKenzie Partners, Inc., +1-212-929-5500; Media Contacts - Steve Littlejohn, VP, Public Affairs, +1-314-702-7556; or Joele Frank or Jamie Moser, both of Joele Frank, Wilkinson Brimmer Katcher, +1-212-355-4449

• 
  phx.corporate-ir.net/phoenix.zhtml?c=69641&p=irol-newsA - [Cached Version]
  Published on: 3/14/2007    Last Visited: 9/11/2007  

  Steve Littlejohn, VP, Public Affairs
  
  (314) 702-7556

• 
  www.insurancenewsnet.com/article.asp?n=1&neID=200806131 - [Cached Version]
  Published on: 6/13/2008    Last Visited: 6/13/2008  

  Investor Contact: David Myers 314.810.3115 david.myers@express-scripts.com Media Contact: Steve Littlejohn 314.996.0981 slittlejohn@express-scripts.com

• 
  www.wdcunet.net/?story=Generic%20Drug's%20Path%20to%20R - [Cached Version]
  Published on: 4/1/2006    Last Visited: 4/30/2006  

  Virtually all of our clients have accepted our recommendations, said Steve Littlejohn, a spokesman for Express Scripts.
  
  The move made sense.Eighty percent of Express Script's plan members who take Lipitor were taking the low-dosage formula, which is equal in strength to Zocor, Littlejohn said.In addition, Zocor is scheduled to lose its patent protection in June 2006, so most patients taking the drug can be switched to a cheaper generic version when it becomes available.Lipitor's patent doesn't expire until 2010.
  
  In a sense what we're doing is helping people get into position to immediately take advantage of the savings when Zocor's generic version becomes available, Littlejohn said.

• 
  www.anzgw.com/employee-benefit-news-otc-claritin-prompt - [Cached Version]
  Last Visited: 12/2/2008  

  "Our goal is to help them realize the best possible cost savings," says Steve Littlejohn, VP of corporate communications for Express Scripts.

• 
  phx.corporate-ir.net/phoenix.zhtml?c=69641&p=irol-newsA - [Cached Version]
  Published on: 11/6/2008    Last Visited: 2/2/2009  

  Steve Littlejohn 314-996-0981

• 
  www.sharewatch.com/story.php?storynumber=96566 - [Cached Version]
  Published on: 11/6/2008    Last Visited: 11/6/2008  

  Express Scripts spokesman Steve Littlejohn said the company delayed publicizing the letter to allow the investigation to take shape, but it had now reached a stage where the company wanted to make it public.

Page:  1 2 3 4 5